

**Media Contact:**  
Garrett D. Smith  
Phone: 240.238.4900  
gsmith@accelovance.com

## **Accelovance Further Defines Vaccine Focus Through Industry Sponsorship**

Rockville, MD – January 3, 2008 – Accelovance announces its sponsorship of two leading vaccine industry events in an effort to increase awareness of its organizational focus on vaccine clinical research. The Phacilitate Vaccine Forum and Terrapinn World Vaccine Congress are both located in the Washington, DC area, a regional hotbed for vaccine research and development from public and private sector organizations.

“Sponsoring events like these allow Accelovance to communicate our focus in this niche industry, vaccine research, at a higher level. Vaccine companies have unique needs and expectations in the execution of their clinical programs and Accelovance is an ideal partner for them,” remarked President and CEO, Stephen J. Trevisan. “We look forward to growing our market exposure in the vaccine industry and increasing our participation at these events.”

Phacilitate Vaccine Forum will be held at the Grand Hyatt hotel in Washington, DC January 24-28. Nearby in Arlington, Virginia, Terrapinn has organized the World Vaccine Congress to take place during April 21-24 at the Crystal City Marriott. Each event draws nearly 500 attendees who represent government, biotech, small and large pharma and industry service providers. The conferences share updates on government funding, vaccine development programs, strategic partnerships, and scientific research while giving industry colleagues the opportunity to network and explore business collaborations. Mr Trevisan commented, “We have enjoyed these events in the past, as attendees, but I am truly excited about our commitment as a sponsor, and the benefits it may bring.”

Accelovance offers nine (9) wholly owned, research dedicated sites, centralized proactive patient recruitment and flexible CRO services from a single clinical services provider. These services have been utilized strategically based on clients needs to drive greater efficiencies in vaccine clinical research. “Our sites, patient recruitment group and CRO team all have the experience and the focus in vaccine research. We have a track record of success in reducing enrollment timelines and offering a cost effective solution. Working for Sponsors directly, or through CROs, Accelovance brings greater control, predictability, and quality assurance to vaccine programs,” said E.B. McLindon, Accelovance Chief Operations Officer.

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique system for delivering quality, on time, and cost effective clinical studies. In China, the Company operates through its wholly-owned foreign enterprise in Beijing as a contract research organization (CRO). Accelovance is focused on optimizing the quality and productivity of multiple clinical sites, through strong central management and targeted pro-active patient recruitment. Delivering high quality and timely clinical trial support services, Accelovance is committed to understanding and meeting its clients needs to contribute to their success.

For more information, visit the company’s website at <http://www.accelovance.com>.